Although we could not evaluate the impact of SGLT2 inhibitors on the incidence of anemia events or the need for ESAs due to the nonplacebo-controlled setting, we believe that the change in hemoglobin level with SGLT2 inhibitor treatment observed in this study was clinically significant. This evidence concerns the gene SLC5A2 and anemia.